Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Val Gebski

Showing results (191-200 of 248) with videos related to

Pageof 25
Sort By:
Gynecologic Oncology|November 23, 2016
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trialRoberto Sorio, Célia Roemer-Becuwe, Felix Hilpert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapseEric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2016
Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE StudyPeter Fox, Rosemary L Balleine, Clara Lee, et al.
Journal of the National Cancer Institute|April 5, 2017
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall SurvivalChee Khoon Lee, Lucy Davies, Yi-Long Wu, et al.
Gynecologic Oncology|November 13, 2024
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancerKatherine Elizabeth Francis, Sandy Simon, Val Gebski, et al.
European Journal of Endocrinology|December 25, 2024
Predicting type 2 diabetes and testosterone effects in high-risk Australian men: development and external validation of a 2-year risk modelKristy P Robledo, Ian C Marschner, Mathis Grossmann, et al.
Annals of Surgical Oncology|March 25, 2017
TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTGTrevor Leong, B Mark Smithers, Karin Haustermans, et al.
Journal of Diabetes and Its Complications|April 22, 2026
Unveiling novel biomarkers for diabetes-related complications through large-scale proteomics analysis: A FIELD sub-studyHabib Francis, Andrzej S Januszewski, Matthew B O'Rourke, et al.
The New England Journal of Medicine|November 1, 2018
Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical CancerPedro T Ramirez, Michael Frumovitz, Rene Pareja, et al.
Scientific Reports|January 25, 2022
VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancerFiona Chionh, Val Gebski, Sheren J Al-Obaidi, et al.
Pageof 25

Showing results (191-200 of 248) with videos related to

Sort By:
Pageof 25
Gynecologic Oncology|November 23, 2016
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trialRoberto Sorio, Célia Roemer-Becuwe, Felix Hilpert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapseEric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2016
Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE StudyPeter Fox, Rosemary L Balleine, Clara Lee, et al.
Journal of the National Cancer Institute|April 5, 2017
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall SurvivalChee Khoon Lee, Lucy Davies, Yi-Long Wu, et al.
Gynecologic Oncology|November 13, 2024
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancerKatherine Elizabeth Francis, Sandy Simon, Val Gebski, et al.
European Journal of Endocrinology|December 25, 2024
Predicting type 2 diabetes and testosterone effects in high-risk Australian men: development and external validation of a 2-year risk modelKristy P Robledo, Ian C Marschner, Mathis Grossmann, et al.
Annals of Surgical Oncology|March 25, 2017
TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTGTrevor Leong, B Mark Smithers, Karin Haustermans, et al.
Journal of Diabetes and Its Complications|April 22, 2026
Unveiling novel biomarkers for diabetes-related complications through large-scale proteomics analysis: A FIELD sub-studyHabib Francis, Andrzej S Januszewski, Matthew B O'Rourke, et al.
The New England Journal of Medicine|November 1, 2018
Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical CancerPedro T Ramirez, Michael Frumovitz, Rene Pareja, et al.
Scientific Reports|January 25, 2022
VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancerFiona Chionh, Val Gebski, Sheren J Al-Obaidi, et al.
Pageof 25